Home » Stocks » KNSA

Kiniksa Pharmaceuticals Ltd. (KNSA)

Stock Price: $14.13 USD 0.30 (2.17%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 965.53M
Revenue (ttm) n/a
Net Income (ttm) -184.45M
Shares Out 32.32M
EPS (ttm) -2.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $14.13
Previous Close $13.83
Change ($) 0.30
Change (%) 2.17%
Day's Open 13.94
Day's Range 13.83 - 14.17
Day's Volume 474,792
52-Week Range 13.77 - 28.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- ARCALYST ® (rilonacept) launched as the first and only FDA-approved therapy for recurrent pericarditis - - Mavrilimumab Phase 2 severe COVID-19 data demonstrated a reduction in mechanical ventilation ...

1 week ago - GlobeNewsWire

- Highest dose cohorts confirm and extend previously-reported 3 mg/kg IV cohort data - - 10 mg/kg IV dose provides full receptor occupancy through Day 71 and complete suppression of TDAR after KLH chall...

1 week ago - GlobeNewsWire

– P rimary endpoint achieved: the proportion of patients alive and free of mechanical ventilation at Day 29 was 12.3 percentage points higher with mavrilimumab versus placebo (p=0.1224 met predefined st...

1 month ago - GlobeNewsWire

- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis – - ARCALYST now available on prescription basis in the U.S. – - Kiniksa One Connect™ program provides ongoing patient ac...

1 month ago - GlobeNewsWire

- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis - - Commercial launch expected in April 2021 - - Kiniksa launches Kiniksa One Connect™ patient support program - - Confer...

1 month ago - GlobeNewsWire

- Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 - - Rilonacept in recurrent pericarditis granted priority review, with PDUFA goal date ...

2 months ago - GlobeNewsWire

HAMILTON, Bermuda, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, Jan...

4 months ago - GlobeNewsWire

- Early signal of efficacy with trends toward lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab –

4 months ago - GlobeNewsWire

– Evaluating vixarelimab across a range of once-monthly dose regimens injected subcutaneously – – Evaluating vixarelimab across a range of once-monthly dose regimens injected subcutaneously –

5 months ago - GlobeNewsWire

- R eceptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous –

5 months ago - GlobeNewsWire

HAMILTON, Bermuda, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, De...

5 months ago - GlobeNewsWire

- PDUFA goal date of March 21, 2021 - - Filing based on positive data from RHAPSODY , which achieved its primary  and all major secondary endpoints - - Rilonacept BLA for CAPS transferred to Kiniksa fro...

5 months ago - GlobeNewsWire

Primary and secondary efficacy endpoints achieved statistical significance; mavrilimumab reduced risk of flare and increased sustained remission Primary and secondary efficacy endpoints achieved statist...

6 months ago - GlobeNewsWire

HAMILTON, Bermuda, Nov. 05, 2020 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological p...

6 months ago - GlobeNewsWire

Kiniksa expects to initiate a dose-ranging Phase 2b clinical trial of vixarelimab in prurigo nodularis in the fourth quarter of 2020 Kiniksa expects to initiate a dose-ranging Phase 2b clinical trial of...

6 months ago - GlobeNewsWire

- Mavrilimumab r educe d t ime - to - f lare and i ncrease d s ustained r emission in Phase 2 giant cell arteritis clinical t rial - - Primary and secondary efficacy endpoints achieved statistical signi...

6 months ago - GlobeNewsWire

- Primary and secondary efficacy endpoints statistically significant - - Primary and secondary efficacy endpoints statistically significant -

7 months ago - GlobeNewsWire

- Virtual e vent to take place from 8:00 a.m. to 9: 3 0 a.m. E D T -

7 months ago - GlobeNewsWire

- Virtual event scheduled for Monday, September 28th, 2020 from 8:00 a.m. to 9:30 a.m. EDT- - Virtual event scheduled for Monday, September 28th, 2020 from 8:00 a.m. to 9:30 a.m. EDT-

7 months ago - GlobeNewsWire

HAMILTON, Bermuda , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Morgan Stanley 18th Annual Global Healthcare Conferenc...

8 months ago - GlobeNewsWire

HAMILTON, Bermuda, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercia...

8 months ago - GlobeNewsWire

HAMILTON, Bermuda, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, A...

9 months ago - GlobeNewsWire

– Rilonacept pivotal Phase 3 trial in recurrent pericarditis met statistical significance for primary and all major secondary efficacy endpoints; sBLA submission expected this year –

9 months ago - GlobeNewsWire

HAMILTON, Bermuda, July 21, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 5,952,381 Class A c...

9 months ago - GlobeNewsWire

HAMILTON, Bermuda, July 20, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of $100.0 million...

9 months ago - GlobeNewsWire

HAMILTON, Bermuda, July 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercia...

10 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) shares were trading higher Monday after the company's Phase 3 trial of Rilonacept showed statistically significant results.

10 months ago - Benzinga

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: EXPI, ICLK, LAKE, VIVO
10 months ago - Zacks Investment Research

HAMILTON, Bermuda, June 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commerciali...

10 months ago - GlobeNewsWire

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: CALX, EXPI, ICLK, STKL
11 months ago - Zacks Investment Research

Kiniksa Positive COVID-19 Data And Other News: The Good, Bad And Ugly Of Biopharma

11 months ago - Seeking Alpha

HAMILTON, Bermuda, June 08, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commerciali...

11 months ago - GlobeNewsWire

HAMILTON, Bermuda, May 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializ...

11 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals (KNSA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

HAMILTON, Bermuda, May 18, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the closing of its public offering of 2,760,000 of its Cla...

11 months ago - GlobeNewsWire

HAMILTON, Bermuda, May 13, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 2,400,000 of its Cla...

1 year ago - GlobeNewsWire

– Mavrilimumab treatment protocol in patients with severe COVID-19 pneumonia and hyperinflammation showed improved clinical outcomes compared to matched contemporaneous controls, including earlier weani...

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor Kiniksa Pharmaceuticals

1 year ago - Zacks Investment Research

- Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 - - Statistically significant secondary efficacy endpoint of imp...

1 year ago - GlobeNewsWire

Kiniksa announced an unexpected move into the COVID-19 furore.

1 year ago - Seeking Alpha

Is (KNSA) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.

Other stocks mentioned: AVRO, FATE, MRSN, NVCR, ORTX, SYBX, TCRR
1 year ago - 24/7 Wall Street

  - All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned -  - Consortium of U.S. academic site...

1 year ago - GlobeNewsWire

- Phase 2 study data show the potential for rilonacept treatment to eliminate or reduce the risk of corticosteroid-associated morbidity in recurrent pericarditis - - Enrollment complete for the pivota...

1 year ago - GlobeNewsWire

These three clinical-stage biotechs could all double in value before year's end.

Other stocks mentioned: ADAP, APLT
1 year ago - The Motley Fool

Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta

1 year ago - GlobeNewsWire

HAMILTON, Bermuda, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa, wi...

1 year ago - GlobeNewsWire

A much-needed vote of confidence lifted an entire industry.

Other stocks mentioned: CGC, PAYC
1 year ago - The Motley Fool

HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2nd Annual Evercore ISI HealthCONx Conference on Wednesd...

1 year ago - GlobeNewsWire

The company's lead drug candidate earned Breakthrough Therapy designation from American regulators.

1 year ago - The Motley Fool

About KNSA

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixa... [Read more...]

Industry
Biotechnology
IPO Date
May 24, 2018
Stock Exchange
NASDAQ
Ticker Symbol
KNSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is 32.75, which is an increase of 131.78% from the latest price.

Price Target
$32.75
(131.78% upside)
Analyst Consensus: Strong Buy